Reversal of cardiac dysfunction by selective ET-A receptor antagonism. - Wikidata - awgldk - TriplyDB

Reversal of cardiac dysfunction by selective ET-A receptor antagonism.

Reversal of cardiac dysfunction by selective ET-A receptor antagonism.

http://www.wikidata.org/entity/Q35545108

about

Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats Endothelin A receptor antagonist, atrasentan, attenuates renal and cardiac dysfunction in Dahl salt-hypertensive rats in a blood pressure independent manner.Improved cardiovascular function with aminoguanidine in DOCA-salt hypertensive rats.Non-human primate and rat cardiac fibroblasts show similar extracellular matrix-related and cellular adhesion gene responses to substance P.Emerging concepts in cardiac matrix biology.The DOCA-Salt Hypertensive Rat as a Model of Cardiovascular Oxidative and Inflammatory Stress L-carnitine attenuates cardiac remodelling rather than vascular remodelling in deoxycorticosterone acetate-salt hypertensive rats.Stress-induced cardiac insufficiency relating to abnormal leptin and FKBP12.6 is ameliorated by CPU0213, an endothelin receptor antagonist, which is not affected by the CYP3A suppressing effect of erythromycin.Murine Models of Heart Failure with Preserved Ejection Fraction: a "Fishing Expedition".Gender differences in adenine-induced chronic kidney disease and cardiovascular complications in rats.

P2860

Q33772867-38018548-27E7-4175-AFFE-2EEBDD72D7A2 Q35182125-710D6AC0-C73F-4A36-828D-58C91BB74401 Q35546284-D85C1E8F-FBEA-41AC-A22A-67B42F1A4E53 Q35821484-BD1E8591-B60B-47E5-903D-061D9659A5E6 Q37661389-CB75CBCB-F7DF-4245-883C-7F644DB8060C Q37951441-1B19F60E-3820-42D8-AFC4-14844168D1AD Q43204912-B41235CE-0EC5-43B3-A9E6-C588F7A1AD18 Q46030445-8AA80BC3-D47A-4942-B594-A92BA8EEE702 Q49203906-3754A4F8-A844-4251-8A14-FA25A7578AA2 Q51114166-7B6274C2-A000-4D6A-A92A-5E811CEAF6DC

P2860

Reversal of cardiac dysfunction by selective ET-A receptor antagonism.

http://www.wikidata.org/entity/Q35545108

description

2005 nî lūn-bûn

@nan

2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Reversal of cardiac dysfunction by selective ET-A receptor antagonism.

@ast

Reversal of cardiac dysfunction by selective ET-A receptor antagonism.

@en

type

label

Reversal of cardiac dysfunction by selective ET-A receptor antagonism.

@ast

Reversal of cardiac dysfunction by selective ET-A receptor antagonism.

@en

prefLabel

Reversal of cardiac dysfunction by selective ET-A receptor antagonism.

@ast

Reversal of cardiac dysfunction by selective ET-A receptor antagonism.

@en

P1433

Q35545108-12413EBB-0DE1-42A6-8ADE-B9E9EC6121BB

P1476

Q35545108-9791B7C1-E416-470E-83E7-079DFB1FF677

P2093

Q35545108-0AB84A0B-3390-4F4C-84AC-B8382C838EAC

Q35545108-6DDE6306-1C1E-4F09-B6DC-357F7703A8B0

Q35545108-838F6AB0-C52D-49D9-9DDF-486D6F3FBFC8

Q35545108-979E5D6E-BB11-4F75-8AA6-EF4C6505E2E8

P2860

Q35545108-1DB818DD-108C-4A3E-A3D2-F2A1ECB3BC44

Q35545108-1E80AC5B-2C24-487E-9988-4470F4AEC207

Q35545108-2DF98930-E82E-42E0-B14A-A3B9B2BD942E

Q35545108-3646320E-F58D-4C2B-8F37-36F00051F573

Q35545108-44D16DAE-7739-4CD3-AA0E-CD92F5E7D98E

Q35545108-53A113E3-122E-4A2B-907E-B540B0C19755

Q35545108-64312B75-78B7-49CA-B34D-8D322AE7CC0A

Q35545108-65FF5C9F-B834-416E-9DDC-34CBE0D1ECE7

Q35545108-7B2B2552-88D9-4A07-A176-7FBD2C9413C9

Q35545108-84D806E9-1BF8-45D0-86C1-B9B70354BD76

P304

Q35545108-7CD977D7-07DE-4A5C-8084-8BA331848696

P31

Q35545108-46B5D923-1091-47EA-8030-A730C11BBF02

P356

Q35545108-C526A744-E3CB-4ADF-B1C4-AB0A1B57A064

P407

Q35545108-D7F3D7DE-9F20-4535-B904-3B841255B6EA

P433

Q35545108-47443622-2855-480D-A8FA-144F059353DE

P478

Q35545108-8BA3F85C-808F-4CF5-8B4E-75BA5E3E0D57

P50

Q35545108-53224B8D-B40C-4FEE-A490-3F0C18AB80C1

P577

Q35545108-DA839858-9201-476C-957C-A01BC1B5F7C8

P5875

Q35545108-88588FAE-F377-4D87-B4B8-CD9EC92B0782

P698

Q35545108-431DCD6B-0373-4240-B8AD-9B1A67A72844

P932

Q35545108-89381870-92EE-4DA8-8684-AF2BEA3158DF

P356

P1433

British Journal of Pharmacology

P1476

Reversal of cardiac dysfunction by selective ET-A receptor antagonism.

@en

P2093

Andrew Fenning

http://www.w3.org/2001/XMLSchema#string

Andrew Hoey

http://www.w3.org/2001/XMLSchema#string

Anthony Allan

http://www.w3.org/2001/XMLSchema#string

Lindsay Brown

http://www.w3.org/2001/XMLSchema#string

P2860

Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats

Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats

Reactive oxygen species mediate Endothelin-1-induced activation of ERK1/2, PKB, and Pyk2 signaling, as well as protein synthesis, in vascular smooth muscle cells

Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling.

Endothelin and cardiac arrhythmias: do endothelin antagonists have a therapeutic potential as antiarrhythmic drugs?

Myocardial fibrosis in DOCA-salt hypertensive rats: effect of endothelin ET(A) receptor antagonism.

Long-term antioxidant administration attenuates mineralocorticoid hypertension and renal inflammatory response.

Role of endothelin in human hypertension.

Role of endothelin-1 in hypertension and vascular disease.

Role of oxidative stress in myocardial hypertrophy and failure.

P304

846-853

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJP.0706384

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

146

http://www.w3.org/2001/XMLSchema#string

P50

P577

2005-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7611534

http://www.w3.org/2001/XMLSchema#string

P698

16151437

http://www.w3.org/2001/XMLSchema#string

P932

1751222

http://www.w3.org/2001/XMLSchema#string